Nuvalent Inc. has identified proto-oncogene tyrosine-protein kinase ROS (ROS1; MCF3) and/or ALK tyrosine kinase receptor inhibitors reported to be useful for the treatment of cancer.

Bristol Myers Squibb Co. has synthesized receptor-interacting serine/threonine-protein kinase 1 (RIPK1; RIP-1) inhibitors reported to be useful for the treatment of inflammatory bowel disease, ...

Pinnacle Food, a provider of smart hydroponic growing systems and technical services, opened for trading this week, raising gross proceeds of ...

In regenerative science, B7-33's potential to influence fibroblast activity and collagen turnover suggests possible implications for tissue repair and wound healing. Given that fibrosis is often a ...

Sutro Biopharma, Inc.’s STRO share price has dipped by 15.38%, which has investors questioning if this is right time to buy.

Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional ...

Research on guinea pig embryos uncovers similarities to human embryogenesis, advancing understanding of preimplantation ...

DelveInsight’s, “Metastatic Colorectal Cancer Pipeline Insight 2025” report provides comprehensive insights about 150+ ...

在结直肠癌（CRC）治疗中，BRAFV600E突变患者预后差，BRAF 和 EGFR 抑制剂联合疗法虽有应用，但存在耐药问题。研究人员开展了关于 LSD1 抑制对 BRAF 突变型 CRC 靶向治疗影响的研究，发现抑制 LSD1 可阻断细胞谱系可塑性，有望改善患者治疗反应。

Daiichi Sankyo seeks Japanese approval for Enhertu to treat patients with HER2 positive metastatic solid tumours: Tokyo Friday, April 25, 2025, 09:00 Hrs [IST] Daiichi Sankyo has ...